H1-antihistamines and urticaria: How can we predict the best drug for our patient?

Clinical and Experimental Allergy

Volumn 42, Issue 10, 2012, Pages 1423-1429

  Church, M K ^a   Maurer, M ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Desloratadine; Fexofenadine; H1 antihistamines; Levocetirizine; Urticaria; Weal and flare

Indexed keywords

CETIRIZINE; DESLORATADINE; FEXOFENADINE; HISTAMINE H1 RECEPTOR ANTAGONIST; LEVOCETIRIZINE;

BIOACCUMULATION; CHRONIC SPONTANEOUS URTICARIA; CLINICAL PRACTICE; DRUG EFFICACY; DRUG MANUFACTURE; DRUG POTENCY; HUMAN; IN VITRO STUDY; PHARMACODYNAMICS; PREDICTIVE VALUE; PRIORITY JOURNAL; REVIEW; TISSUE DISTRIBUTION; TREATMENT OUTCOME; TREATMENT RESPONSE; URTICARIA;

ANTI-ALLERGIC AGENTS; CETIRIZINE; HISTAMINE; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; LORATADINE; PREDICTIVE VALUE OF TESTS; SKIN TESTS; TERFENADINE; URTICARIA;

EID: 84866626291     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2012.03957.x     Document Type: Review

References (36)

1. Zuberbier T, Asero R, Bindslev-Jensen C et al. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy 2009; 64:1427-43.
2. Grattan CE, Humphreys F. Guidelines for evaluation and management of urticaria in adults and children. Br J Dermatol 2007; 157:1116-23.
3. Maurer M, Weller K, Bindslev-Jensen C et al. Unmet clinical needs in chronic spontaneous urticaria. A GA(2) LEN task force report(1). Allergy 2011; 66:317-30.
4. Petersen LJ, Church MK, Skov PS. Histamine is released in the weal but not the flare following challenge of human skin in vivo: A microdialysis study. Clin Exp Allergy 1997; 27:284-96.
5. Stenken JA, Church MK, Gill CA, Clough GF. How minimally invasive is microdialysis sampling? A cautionary note for cytokine collection in human skin and other clinical studies. AAPS J 2010; 12:73-8.
6. Wedi B, Kapp A. Chronic urticaria: assessment of current treatment. Expert Rev Clin Immunol 2005; 1:459-73.
7. Powell RJ, Du Toit GL, Siddique N et al. BSACI guidelines for the management of chronic urticaria and angio-oedema. Clin Exp Allergy 2007; 37:631-50.
8. 1-antagonists: receptor affinity versus selectivity. Inflamm Res 2003; 52(Suppl. 1):S49-S50.
9. Gillard M, Benedetti MS, Chatelain P, Baltes E. Histamine H1 receptor occupancy and pharmacodynamics of second generation H1-antihistamines. Inflamm Res 2005; 54:367-9.
10. Molimard M, Diquet B, Benedetti MS. Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. Fundam Clin Pharmacol 2004; 18:399-411.
11. Lewis T. The blood vessels of human skin and their responses. London: Shaw & Son, 1927.
12. Galeno TM, Knuepfer MM, Brody MJ. Vasodilator response to histamine: dependence upon the site of administration. Eur J Pharmacol 1979; 56:257-60.
13. Bull HA, Cohen J, Dowd PM. Responses of human dermal microvascular endothelial cells to histamine and their modulation by interleukin 1 and substance P. J Invest Dermatol 1991; 97:787-92.
14. Darsow U, Ring J, Scharein E, Bromm B. Correlations between histamine-induced wheal, flare and itch. Arch Dermatol Res 1996; 288:436-41.
15. Petersen LJ, Church MK, Skov PS. Histamine is released in the wheal but not the flare following challenge of human skin in vivo: a microdialysis study. Clin Exp Allergy 1997; 27:284-95.
16. Schmelz M, Schmidt R, Bickel A, Handwerker HO, Torebjork HE. Specific C-receptors for itch in human skin. J Neurosci 1997; 17:8003-8.
17. Grant JA, Riethuisen JM, Moulaert B, DeVos C. A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects. Ann Allergy Asthma Immunol 2002; 88:190-7.
18. Purohit A, Melac M, Pauli G, Frossard N. Twenty-four-hour activity and consistency of activity of levocetirizine and desloratadine in the skin. Br J Clin Pharmacol 2003; 56:388-94.
19. Frossard N, Strolin-Benedetti M, Purohit A, Pauli G. Inhibition of allergen-induced wheal and flare reactions by levocetirizine and desloratadine. Br J Clin Pharmacol 2008; 65:172-9.
20. Simons FE, Silver NA, Gu X, Simons KJ. Skin concentrations of H1-receptor antagonists. J Allergy Clin Immunol 2001; 107:526-30.
21. Gillard M, Van der PC, Moguilevsky N, Massingham R, Chatelain P. Binding characteristics of cetirizine and levocetirizine to human H(1) histamine receptors: contribution of Lys(191) and Thr(194). Mol Pharmacol 2002; 61:391-9.
22. Petersen LJ, Church MK, Rihoux JP, Skov PS. Measurement of interstitial cetirizine concentrations in human skin: correlation of drug levels with inhibition of histamine-induced skin responses. Allergy 1999; 54:607-11.
23. Monroe EW, Daly AF, Shalhoub RF. Appraisal of the validity of histamine-induced wheal and flare to predict the clinical efficacy of antihistamines. J Allergy Clin Immunol 1997; 99:S798-806.
24. Devillier P, Bousquet J. Inhibition of the histamine-induced weal and flare response: a valid surrogate measure for antihistamine clinical efficacy? Clin Exp Allergy 2007; 37:400-14.
25. Denham KJ, Boutsiouki P, Clough GF, Church MK. Comparison of the effects of desloratadine and levocetirizine on histamine-induced wheal, flare and itch in human skin. Inflamm Res 2003; 52:424-7.
26. Passalacqua G, Guerra L, Compalati E et al. Comparison of the effects in the nose and skin of a single dose of desloratadine and levocetirizine over 24 hours. Int Arch Allergy Immunol 2004; 135:143-7.
27. Popov TA, Dumitrascu D, Bachvarova A, Bocsan C, Dimitrov V, Church MK. A comparison of levocetirizine and desloratadine in the histamine-induced wheal and flare response in human skin in vivo. Inflamm Res 2006; 55:241-4.
28. Klos K, Kruszewski J, Kruszewski R, Sulek K. [The effect of 5-days of cetirizine, desloratadine, fexofenadine 120 and 180 mg, levocetirizine, loratadine treatment on the histamine-induced skin reaction and skin blood flow-a randomized, double-blind, placebo controlled trial]. Pol Merkur Lekarski 2006; 21:449-53.
29. Kruszewski J, Klos K, Sulek K. [Inhibition of histamine-induced wheel after a recommended single dose administration of 10 mg cetirizine, 5 mg desloratadine, 120 i 180 mg fexofenadine, 5 mg levocetirizine and 10 mg loratadine-a randomized, double-blind, placebo controlled trial]. Pol Merkur Lekarski 2006; 21:443-8.
30. Meltzer EO, Gillman SA. Efficacy of fexofenadine versus desloratadine in suppressing histamine-induced wheal and flare. Allergy Asthma Proc 2007; 28:67-73.
31. Dhanya NB, Thasleem Z, Rai R, Srinivas CR. Comparative efficacy of levocetirizine, desloratidine and fexofenadine by histamine wheal suppression test. Indian J Dermatol Venereol Leprol 2008; 74:361-3.
32. Potter PC, Kapp A, Maurer M et al. Comparison of the efficacy of levocetirizine 5 mg and desloratadine 5 mg in chronic idiopathic urticaria patients. Allergy 2009; 64:596-604.
33. Hong JB, Lee HC, Hu FC, Chu CY. A randomized, double-blind, active-controlled, parallel-group pilot study to compare the efficacy and sedative effects of desloratadine 5 mg with levocetirizine 5 mg in the treatment of chronic idiopathic urticaria. J Am Acad Dermatol 2010; 63:e100-2.
34. Staevska M, Popov TA, Kralimarkova T et al. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy Clin Immunol 2010; 125:676-82.
35. Simons FE, Simons KJ. Levocetirizine: pharmacokinetics and pharmacodynamics in children age 6 to 11 years. J Allergy Clin Immunol 2005; 116:355-61.
36. Simons KJ, Benedetti MS, Simons FE, Gillard M, Baltes E. Relevance of H1-receptor occupancy to H1-antihistamine dosing in children. J Allergy Clin Immunol 2007; 119:1551-4.